| Deler fremragende | 75,851,722 shares |
| Insideraktier | 27.921.493 shares |
| Insider ejerskab | 36,81 % |
| Total Insiders | 49 |
Insider-stemningsscore
Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.
Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.
Officers sentiment score
Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.
Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.
Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.
Nøgle Insider Metrics
Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.
For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).
Insiderhandelsdiagram
Eledon Pharmaceuticals, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.
Insiderliste og lønsomhedsmålinger
Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.
See our leaderboard of most profitable insider traders.
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
|
Apple Tree Partners Ii Lp
Director, 10% Owner -
[D]
|
4.218.641 | 4.218.641 | |
|
Apple Tree Partners II - Annex, L.P.
Director, 10% Owner -
[D]
|
3.568.438 | 3.568.438 | |
|
Apple Tree Partners IV, L.P.
Director, 10% Owner -
[D]
|
250.000 | 250.000 | |
| Timothy J Barberich Director - [D] | 121.077 | 121.077 | |
| Biotechnology Value Fund Ii Lp - | 113.152 | 220.460 | |
| Biotechnology Value Fund L P - | 113.152 | 220.460 | |
|
Bvf Gp Holdings Llc
10% Owner -
|
113.152 | 220.460 | |
| Bvf I Gp Llc - | 113.152 | 220.460 | |
| Bvf Ii Gp Llc - | 113.152 | 220.460 | |
|
Bvf Inc/il
10% Owner -
|
113.152 | 220.460 | |
|
Bvf Partners L P/il
10% Owner -
|
220.460 | 220.460 | |
| BVF Partners OS Ltd. - | 113.152 | 220.460 | |
| Biotechnology Value Trading Fund OS LP - | 113.152 | 220.460 | |
| Buckley Stephen Jr. Director - [D] | 11.000 | 11.000 | |
| Erez Chimovits Director - [D] | 3.183.314 | 3.183.314 | |
| Cheryl Cohen Director - [D] | 0 | 0 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Flesher Gregory J. Chief Executive Officer, Director - [D] [O] | 156.918 | 156.918 | |
| Karen Jean Ferrante | 62.000 | ||
| David-Alexandre C Gros Chief Executive Officer, Director - [D] [O] | 9.000 | 9.000 | |
|
Seth Loring Harrison
Director, 10% Owner -
[D]
|
7.912.079 | 7.912.079 | |
| Jan Hillson Director - [D] | 3.430 | 3.430 | |
| Lee Kalowski Chief Financial Officer - [O] | 40.953 | 40.953 | |
| Keith Katkin Director - [D] | 8.575 | 8.575 | |
| Kessler David A. | 12.000 | ||
| Allan Kirk Director - [D] | 3.430 | 3.430 | |
| Jon Kuwahara See Remarks - [O] | 5.974 | 5.974 | |
|
Mark N Lampert
10% Owner -
|
113.152 | 220.460 | |
|
Lifesci Index Partners Llc
10% Owner -
|
1.065.867 | 1.065.867 | |
| Gary A Lyons Director - [D] | 0 | 0 | |
| June Lee Director - [D] | 3.430 | 3.430 | |
| Paul Sean Little CHIEF FINANCIAL OFFICER - [O] | 10.000 | 10.000 | |
|
Logos Global Management LP
10% Owner -
|
224.071 | 224.071 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| McBride John S. Director - [D] | 3.430 | 3.430 | |
| Jodie Pope Morrison President and CEO, Director - [D] [O] | 57.566 | 57.566 | |
|
Ag Novartis
10% Owner -
|
4.493.458 | 4.493.458 | |
|
Bioventures Ltd Novartis
10% Owner -
|
4.493.458 | 4.493.458 | |
| Christine Ocampo See Remarks - [O] | 23.160 | 23.160 | |
| Walter C Ogier | 20.000 | ||
|
OrbiMed Israel BioFund GP Limited Partnership
Director, 10% Owner -
[D]
|
73.650 | 73.650 | |
|
OrbiMed Israel GP Ltd.
10% Owner -
|
73.650 | 73.650 | |
| Steven Perrin President, Director - [D] [O] | 1.000 | 1.000 | |
| Gerald E Quirk | 62.000 | ||
| Robinson James A. Jr. Director - [D] | 3.430 | 3.430 | |
|
Muneer A Satter
10% Owner -
|
1.771.688 | 1.771.688 | |
| Smith Bryan E. | 120.000 | ||
| Turkel Catherine C. President - [O] | 88.662 | 88.662 | |
|
Martin D Williams
10% Owner -
|
337.700 | 337.700 | |
|
Paul Yook
10% Owner -
|
1.065.867 | 1.065.867 | |
| Yanchik Joseph A., III Director - [D] | 51.092 | 51.092 |
Report errors via our new Insider Auditing Tool
Track Records af insiderkøb - Kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ELDN / Eledon Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Track Records af insidersalg - Kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ELDN / Eledon Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Transaktionshistorik
Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.
| Fil Dato |
Handle Dato |
Form | Insider | Ticker | Sikkerhedstitel | Kode | Direkte | Dyrke motion Pris |
Enhed Pris |
Enheder Ændret |
Værdi Ændret (1K) |
Tilbage Muligheder |
Tilbage Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | 2026-01-10 | 4 | Robinson James A. Jr. | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Lee June | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Katkin Keith | ELDN | Common Stock | D | 8.575 | 8.575 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Kirk Allan | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Hillson Jan | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | McBride John S. | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 75.431 | 220.460 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 821.121 | 2.633.679 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1.031.385 | 3.361.803 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 86.341 | 145.029 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 837.146 | 1.812.558 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1.055.445 | 2.330.418 | ||||||
| 2022-11-23 | 2022-11-23 | 4 | Perrin Steven | ELDN | Common Stock | D | 2,5969 | 1.000 | 3 | 1.000 | ||||
| 2022-02-02 | 2022-02-01 | 4 | Gros David-Alexandre C | ELDN | Stock Option (right to buy) | D | 3,97 | 108.000 | 108.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Smith Bryan E. | ELDN | Stock Option (right to buy) | D | 3,97 | 120.000 | 120.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Ogier Walter C | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Perrin Steven | ELDN | Stock Option (right to buy) | D | 3,97 | 155.000 | 155.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | McBride John S. | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | LYONS GARY A | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Lee June | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Hillson Jan | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Katkin Keith | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Little Paul Sean | ELDN | Stock Option (right to buy) | D | 3,97 | 155.000 | 155.000 | |||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 975.412 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 1.274.973 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 58.688 | ||||||||
| 2021-12-21 | 2021-12-20 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 4,4800 | 2.000 | 9 | 9.000 | ||||
| 2021-08-19 | 2021-08-17 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 6,2100 | 4.000 | 25 | 7.000 | ||||
| 2021-06-14 | 2021-06-11 | 4 | Little Paul Sean | ELDN | Common Stock | D | 8,8700 | 10.000 | 89 | 10.000 | ||||
| 2021-06-10 | 2021-06-09 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 8,0100 | 3.000 | 24 | 3.000 | ||||
| 2021-05-04 | 2021-05-03 | 4 | Smith Bryan E. | ELDN | Stock Option (Right to Buy) | D | 9,91 | 158.500 | 158.500 | |||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -1.757 | 6.758 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -9.169 | 39.693 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -11.776 | 52.145 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -35 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -203 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -273 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 97.615 | 113.152 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 1.944 | 15.537 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 509.410 | 598.624 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 11.278 | 89.214 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 654.215 | 771.780 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 15.166 | 117.565 | ||||||
| 2020-12-04 | 2020-12-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 21,6000 | -103.200 | -2.229 | 73.650 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,5507 | 9.098 | 232 | 224.071 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,1740 | 15.000 | 393 | 214.973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 27,0200 | -27 | -1 | 199.973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,8790 | 12.942 | 335 | 200.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,6442 | -12.942 | -345 | 187.058 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,4824 | 15.000 | 397 | 200.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,9730 | 4.000 | 104 | 185.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24,5299 | 31.000 | 760 | 181.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24,0325 | 5.000 | 120 | 150.000 | ||||
| 2020-11-06 | 3 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 145.000 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 77.936 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 102.400 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 13.595 | ||||||||
| 2020-09-15 | 2020-09-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 500,00 | 1.167 | 1.167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 500,00 | 1.167 | 1.167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 500,00 | 2.145 | 2.145 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 500,00 | 5.907 | 5.907 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Gros David-Alexandre C | NVUS | Stock Option (Right to Buy) | D | 500,00 | 18.278 | 18.278 | |||||
| 2020-03-20 | 2020-03-19 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0,26 | 50.000 | 50.000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0,26 | 100.000 | 100.000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0,26 | 200.000 | 200.000 | |||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | |||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | |||||
| 2019-09-30 | 2019-09-26 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0,67 | 100.000 | 100.000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0,67 | 75.000 | 75.000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0,67 | 60.000 | 60.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Chimovits Erez | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-05-22 | 2019-05-21 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1,9114 | -2.937 | -6 | 156.918 | ||||
| 2019-05-22 | 2019-05-20 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1,9616 | -11.701 | -23 | 159.855 | ||||
| 2019-05-22 | 2019-05-21 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1,9114 | -1.058 | -2 | 5.974 | ||||
| 2019-05-22 | 2019-05-20 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1,9616 | -4.218 | -8 | 7.032 | ||||
| 2019-05-22 | 2019-05-21 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1,9114 | -1.914 | -4 | 88.662 | ||||
| 2019-05-22 | 2019-05-20 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1,9616 | -7.623 | -15 | 90.576 | ||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez | NVUS | Common Stock | I | 3,1000 | 646.204 | 2.003 | 3.183.314 | ||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 3,1000 | 646.204 | 2.003 | 3.183.314 | ||||
| 2019-05-02 | 2019-04-30 | 4 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, par value $0.01 per share | I | 2,7000 | -200 | -1 | 1.065.867 | ||||
| 2019-03-18 | 2019-03-14 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 3,72 | 25.000 | 25.000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 3,72 | 90.000 | 90.000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 25.000 | 171.556 | ||||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 3,72 | 50.000 | 50.000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20.000 | 98.199 | ||||||
| 2018-09-13 | 2018-09-12 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 5,0190 | 16.632 | 83 | 78.199 | ||||
| 2018-09-13 | 2018-09-11 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 4,5560 | 17.048 | 78 | 61.567 | ||||
| 2018-09-07 | 2018-09-05 | 4 | TURKEL CATHERINE C. By Spouse's IRA | NVUS | Common Stock | I | 3,9660 | 805 | 3 | 805 | ||||
| 2018-06-14 | 2018-06-13 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4,83 | 24.000 | 24.000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20.000 | 44.519 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 4,83 | 56.500 | 56.500 | |||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 30.700 | 146.556 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 4,83 | 12.000 | 12.000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 11.250 | 11.250 | ||||||
| 2017-11-06 | 2017-11-06 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4,21 | 50.000 | 50.000 | |||||
| 2017-07-10 | 2017-07-10 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 5,61 | 35.000 | 35.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 5,85 | 36.000 | 36.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Morrison Jodie Pope | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-05-26 | 2017-05-24 | 4 | OCAMPO CHRISTINE | NVUS | Stock Option (Right to Buy) | D | 5,50 | 52.500 | 52.500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 5,50 | 52.500 | 52.500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 5,50 | 250.000 | 250.000 | |||||
| 2017-05-11 | 3 | LYONS GARY A | NVUS | No Securities Owned | D | 0 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113.794 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113.794 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26.816 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26.816 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24.238 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24.238 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23.160 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23.160 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5.074.220 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5.074.220 | ||||||||
| 2017-05-11 | 2017-05-10 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 9,9900 | 58.959 | 589 | 115.856 | ||||
| 2017-05-11 | 2017-05-10 | 4 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 9,9900 | 10.010 | 100 | 21.590 | ||||
| 2017-05-11 | 2017-05-10 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 9,9900 | 11.111 | 111 | 24.519 | ||||
| 2017-05-11 | 2017-05-09 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 2.537.110 | 2.537.110 | ||||||
| 2016-06-16 | 2016-06-15 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-16 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-03-15 | 2016-03-15 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 5,7400 | 8.000 | 46 | 11.000 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,37 | -20.000 | 37.878 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -8.015 | 0 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,3700 | 20.000 | 27 | 57.566 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 8.015 | 5 | 37.566 | ||||
| 2015-12-17 | 2015-12-15 | 4 | Ferrante Karen Jean | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 9,65 | 189.000 | 189.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-11-12 | 2015-11-11 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 11,2500 | 3.000 | 34 | 3.000 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -13.500 | 186.678 | |||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0100 | -13.500 | -189 | 0 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 13.500 | 57 | 13.500 | ||||
| 2015-09-08 | 2015-09-08 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13,1300 | -4.668 | -61 | 40.953 | ||||
| 2015-09-04 | 2015-09-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 12,9600 | -2.158 | -28 | 45.621 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,37 | -3.000 | 57.878 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -7.000 | 8.015 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -564 | 312.736 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,3700 | 3.000 | 4 | 29.551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 7.000 | 4 | 26.551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -564 | -8 | 19.551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 564 | 1 | 20.115 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -12.000 | 313.300 | |||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -12.000 | -164 | 19.551 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 12.000 | 19 | 31.551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -7.426 | 15.015 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 2,31 | -2.574 | 0 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 7.426 | 5 | 19.551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 2,3100 | 2.574 | 6 | 12.125 | ||||
| 2015-07-17 | 2015-07-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2580 | -3.566 | -51 | 4.493.458 | ||||
| 2015-07-15 | 2015-07-14 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,4100 | -27.861 | -401 | 4.497.024 | ||||
| 2015-07-15 | 2015-07-13 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2020 | -20.611 | -293 | 4.524.885 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -8.000 | 325.300 | |||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -8.000 | -110 | 9.551 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 8.000 | 13 | 17.551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -8.000 | 333.300 | |||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,8300 | -8.000 | -111 | 9.551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 8.000 | 13 | 17.551 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -300 | 200.178 | |||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 14,2000 | -300 | -4 | 0 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 300 | 1 | 300 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -6.700 | 200.478 | |||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0000 | -6.700 | -94 | 0 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 6.700 | 28 | 6.700 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -2.000 | 207.178 | |||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0200 | -2.000 | -28 | 0 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 2.000 | 8 | 2.000 | ||||
| 2015-06-19 | 2015-06-17 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-18 | 2015-06-16 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2700 | -1.120 | -16 | 4.545.496 | ||||
| 2015-06-16 | 2015-06-12 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -5.919 | -84 | 4.561.393 | ||||
| 2015-06-16 | 2014-06-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -14.777 | -210 | 4.546.616 | ||||
| 2015-06-12 | 2015-06-11 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -27.875 | -396 | 4.567.312 | ||||
| 2015-05-28 | 2015-05-26 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 10,81 | 214.605 | 214.605 | |||||
| 2015-04-20 | 2015-04-16 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13,0000 | -4.567 | -59 | 47.779 | ||||
| 2015-04-13 | 3 | Cohen Cheryl | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-04-13 | 2015-04-09 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 11,08 | 25.000 | 25.000 | |||||
| 2015-04-06 | 2015-04-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 11,4500 | -2.258 | -26 | 52.346 | ||||
| 2015-03-20 | 2015-03-19 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,5000 | -46.141 | -669 | 4.595.187 | ||||
| 2015-03-20 | 2015-03-18 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,5000 | -3.000 | -44 | 4.641.328 | ||||
| 2015-01-12 | 3 | Buckley Stephen Jr. | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-01-12 | 2015-01-08 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14,49 | 25.000 | 25.000 | |||||
| 2014-10-17 | 2014-10-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 13,25 | 134.134 | 134.134 | |||||
| 2014-10-17 | 2014-10-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 13,25 | 50.671 | 50.671 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series E Preferred Stock | I | -8.013.003 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-3 Preferred Stock | I | -3.931.085 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-2 Preferred Stock | I | -457.728 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-1 Preferred Stock | I | -4.577.315 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 15,0000 | 150.000 | 2.250 | 1.771.688 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 1.621.688 | 1.621.688 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series E Preferred Stock | I | -24.199.308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-3 Preferred Stock | I | -24.046.035 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-2 Preferred Stock | I | -1.539.643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-1 Preferred Stock | I | -8.711.335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series C Preferred Stock | I | -14.604.833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-2 Preferred Stock | I | -644.786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-1 Preferred Stock | I | -798.067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series A Preferred Stock | I | -4.500.000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 15,0000 | 362.500 | 5.438 | 7.912.079 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 7.549.570 | 7.549.579 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series E Preferred Stock | D | -24.199.308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series D-3 Preferred Stock | D | -10.675.613 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 15,0000 | 237.500 | 3.562 | 3.568.438 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 3.330.938 | 3.330.938 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | 165.251 | 165.251 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series E Preferred Stock | D | -15.064.469 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-3 Preferred Stock | D | -13.222.826 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-2 Preferred Stock | D | -1.539.643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-1 Preferred Stock | D | -15.396.431 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 15,0000 | 325.000 | 4.875 | 4.644.328 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 4.319.328 | 4.319.328 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series E Preferred Stock | D | -809.955 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series D-3 Preferred Stock | D | -457.731 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Common Stock | D | 121.077 | 121.077 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-3 Preferred Stock | D | -13.370.422 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-2 Preferred Stock | D | -1.539.643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-1 Preferred Stock | D | -8.711.335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series C Preferred Stock | D | -14.604.833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-2 Preferred Stock | D | -644.786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-1 Preferred Stock | D | -798.067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series A Preferred Stock | D | -4.500.000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 4.218.632 | 4.218.641 | ||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250.000 | ||||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250.000 | ||||||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 15,00 | 218.417 | 218.417 | |||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Common Stock | D | 54.604 | 54.604 | ||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19.102 | ||||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19.102 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51.092 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51.092 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337.700 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337.700 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212.712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425.397 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212.712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425.397 |
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
